Abstract 615P
Background
Vascular endothelial growth factor receptor (VEGFR) inhibitors have demonstrated promising activity for recurrent and unresectable osteosarcoma. However, the use of VEGFR inhibitor for pulmonary metastatic osteosarcoma to improve resectability and postoperative outcome remains unexplored.
Methods
We did a single-arm phase 2 trial investigating the efficacy of adding anti-angiogenics to chemo for resectable pulmonary metastases (PMs) of osteosarcoma. Pts received VEGFR inhibitor Apatinib plus gemcitabine-docetaxel for 3 cycles pre- and 4 cycles post-metastasectomy, followed by Apatinib monotherapy maintenance until disease progression or unacceptable toxicities. Our primary endpoint was 12-month progression-free rate (12m-PFR) with a historical control of <30%. The primary endpoint would be met if ≥17 out of 39 evaluable pts were considered non-progression, corresponding to a pre-specified 12m-PFR of 50%.
Results
We enrolled 43 pts from Mar 2019 to Nov 2022 in this study, with 23 (54%) having ≥4 PMs, 12 (28%) having ≥10 PMs, and 24 (56%) having bilateral PMs. Extra tiny PMs were commonly detected and resected during surgical exploration. 39/43 pts (91%) finished their surgical procedures as planned, while 1 pt encountered tumor progression before metastasectomy and 3 failed to undergo the 2nd-stage metastasectomy after the 1st stage. Two pts were excluded from efficacy analysis due to major protocol violations. Of the remaining 41 pts, tumor volume reduction was seen in 30 (73.2%) pts before surgery, and 18 of the first 39 evaluable pts were progression-free at 12m (primary endpoint met). In the safety analysis (43 pts), ≥grade 3 toxicities were noticed in 29(67%) pts. One of the 15 deaths was due to post-operative complications and the remaining (14/15) due to tumor progression. The most common grade 3–4 toxicies were thrombocytopenia (26%), proteinuria (16%), anemia (14%), granulocytopenia(12%), pain(9.3%), pneumothorax(9.3%). Of note, only 2 ≥grade 3 postoperative wound problems following VEGFR inhibitor were observed.
Conclusions
Our study demonstrated a potential activity of combining Apatinib plus chemotherapy with metastasectomy for treating pulmonary metastatic osteosarcoma.
Clinical trial identification
NCT03742193.
Editorial acknowledgement
We are wholeheartedly gratefull to all participants and their parents in this study.
Legal entity responsible for the study
Ruijin Hospital, Shanghai Jiaotong University.
Funding
Shanghai Municipal Health Commission (grant No. 202140124) National Science Foundation of China (grant No. 82141116) Natural Science Foundation of Shanghai (grant No. 20ZR1434000).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
601P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Xiaohua Wu
Session: Poster Display
Resources:
Abstract
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract